DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz Z. et al
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-breast 3): A randomised, open-label, multicentre, phase 2 trial.
Lancet Oncol 2015;
16: 1700-10
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.